Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Practical application of the virtual crossmatch.

Steven Zangwill1, Thomas Ellis, Gail Stendahl

  • 1Department of Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI 53226, USA. szangwill@chw.org

Pediatric Transplantation
|August 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Anti-HLA Antibody Desensitization Strategies in Pediatric Heart Transplant Recipients: A PHTS-PHIS Linkage Analysis.

Pediatric transplantation·2026
Same author

MRI and MRA Sensitivity and Specificity for Accurate Diagnosis of Labral Tear for Patients Undergoing Hip Arthroscopy With Concomitant Periacetabular Osteotomy.

Orthopaedic journal of sports medicine·2025
Same author

Early Experience With Percutaneous Pulmonary Blood Flow Restrictors to Allow Deferral of Norwood Surgery.

World journal for pediatric & congenital heart surgery·2025
Same author

The Challenge of Pediatric Heart Transplantation in a Failing Fontan Patient With Dextrocardia and Heterotaxy Syndrome.

World journal for pediatric & congenital heart surgery·2025
Same author

Prolonged Biventricular Berlin Heart EXCOR Support as a Bridge to Heart Transplantation in an Infant: The Victory of Little Warrior.

Circulation. Heart failure·2025
Same author

Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial.

JAMA·2025
Same journal

Living-Donor Kidney Transplantation Between Mother and Son With Clinically Confirmed Hereditary Angioedema.

Pediatric transplantation·2026
Same journal

EXPRESSION OF CONCERN: Tacrolimus-Related Seizure After Pediatric Liver Transplantation - A Single-Center Experience.

Pediatric transplantation·2026
Same journal

Early Neurological Complications Following Pediatric Liver Transplantation.

Pediatric transplantation·2026
Same journal

Early Response to Therapeutic Plasma Exchange as a Prognostic Indicator in Pediatric Liver Transplant Recipients with Early Allograft Dysfunction.

Pediatric transplantation·2026
Same journal

Why Do Adolescents and Young Adults Continue to Have the Worst Kidney Transplant Outcomes?

Pediatric transplantation·2026
Same journal

International Perspectives on Pediatric Split-Liver Allocation: A Review of Policy Frameworks and the Swiss Experience.

Pediatric transplantation·2026
See all related articles

The Virtual Crossmatch (VXM) significantly reduces heart transplant wait times and improves survival rates in sensitized children. This method aids in risk stratification, offering a better alternative to traditional prospective crossmatch requirements.

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation Medicine

Background:

  • Human Leukocyte Antigen (HLA) antibody sensitization is a critical risk factor for heart transplant complications.
  • The Virtual Crossmatch (VXM) has shown predictive value for acute incompatibility in vitro.
  • Clinical application of VXM in sensitized pediatric heart transplant candidates is reviewed.

Purpose of the Study:

  • To evaluate the impact of the Virtual Crossmatch (VXM) on wait times for pediatric heart transplant candidates.
  • To assess the effect of VXM on survival outcomes in sensitized children undergoing heart transplantation.
  • To compare VXM with traditional crossmatch strategies.

Main Methods:

  • Study included patients listed for heart transplantation at Children's Hospital of Wisconsin.

Related Experiment Videos

  • Sensitization defined by PRA > 10% or identified HLA-specific antibodies.
  • Statistical analysis included Fisher's exact test and unpaired t-test.

    • Main Results:

    • 23% sensitization rate observed in 111 listed patients.
    • VXM group (n=10) had 100% survival and a median wait time of 65 days.
    • Prospective crossmatch group (n=8) had 87.5% mortality and a median wait time of 119 days.
    • VXM demonstrated high concordance with retrospective crossmatch results.

    Conclusions:

    • VXM implementation as a listing strategy can shorten wait times and improve outcomes for sensitized pediatric heart transplant recipients.
    • VXM facilitates patient risk stratification, aiding in donor offer evaluation.
    • VXM serves as a viable alternative to prospective crossmatch requirements, though other advancements may also contribute to improved outcomes.